Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;12(2):117-29.
doi: 10.1038/nrd3838. Epub 2013 Jan 21.

Targeting eosinophils in allergy, inflammation and beyond

Patricia C Fulkerson  1 , Marc E Rothenberg
Affiliations
Review

Targeting eosinophils in allergy, inflammation and beyond

Patricia C Fulkerson et al. Nat Rev Drug Discov. 2013 Feb.

Abstract

Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic disorders such as asthma and allergy, as well as diseases that are not primarily associated with eosinophils, such as autoimmunity and malignancy. Eosinophil-targeted therapeutic agents that are aimed at blocking specific steps involved in eosinophil development, migration and activation have recently entered clinical testing and have produced encouraging results and insights into the role of eosinophils. In this Review, we describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight strategies for using personalized medicine to treat eosinophilic disorders.

PubMed Disclaimer

References

    1. Lee JJ, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773–1776. - PubMed
    1. Humbles AA, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776–1779. - PubMed
    1. Castro M, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit Care Med. 2011;184:1125–1132. - PubMed
    1. Haldar P, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009;360:973–984. - PMC - PubMed
    1. Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012 - PMC - PubMed

Publication types